These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 21791194)

  • 1. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.
    D'Addio A; Curti A; Worel N; Douglas K; Motta MR; Rizzi S; Dan E; Taioli S; Giudice V; Agis H; Kopetzky G; Soutar R; Casadei B; Baccarani M; Lemoli RM
    Bone Marrow Transplant; 2011 Mar; 46(3):356-63. PubMed ID: 20577218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.
    Arcaini L; Laszlo D; Rizzi S; Balzarotti M; Antoniazzi F; Zilioli VR; Guggiari E; Farina L; Todisco E; Bonfichi M; Alamos SM; Rossi G; Martinelli G; Morra E
    Leuk Res; 2011 Jun; 35(6):712-4. PubMed ID: 21276613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
    Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
    Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma.
    Cashen A; Lopez S; Gao F; Calandra G; MacFarland R; Badel K; DiPersio J
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1253-61. PubMed ID: 18940680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
    Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plerixafor use in patients with previous mobilization failure: A multicenter experience.
    Tekgündüz E; Altuntaş F; Sıvgın S; Akı SZ; Dönmez A; Topçuoğlu P; Yıldırım R; Baysal NA; Ayyıldız E; Yüksel MK; Sarı I; Tombuloğlu M; Unal A; Ilhan O
    Transfus Apher Sci; 2012 Aug; 47(1):77-80. PubMed ID: 22609192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.
    Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
    Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
    Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.
    Sánchez-Ortega I; Querol S; Encuentra M; Ortega S; Serra A; Sanchez-Villegas JM; Grifols JR; Pujol-Balaguer MM; Pujol-Bosch M; Martí JM; Garcia-Cerecedo T; Barba P; Sancho JM; Esquirol A; Sierra J; Duarte RF
    Bone Marrow Transplant; 2015 Jan; 50(1):34-9. PubMed ID: 25222503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M
    Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.